Coloplast CEO on FDA ban: "We are disappointed"
CEO in Coloplast Kristian Villumsen is disappointed over FDA's decision to ban the company's transvaginal synthetic mesh product although the prohibition only has marginal impact on Coloplast's revenue. However, analyst calls the case "bad news" for the company.
Coloplast is disappointed with the US Food and Drug Agency's decision to remove the company's surgical transvaginal mesh Restorelle DirectFix Anterior as a treatment option for women with pelvic organ prolapse.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
